Abiraterone Acetate has 5 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Thioridazine, Dextromethorphan, Rifampin. Patients taking Abiraterone Acetate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Contraindicated
- 1
- Major
- 2
- Moderate
- 1
- Minor
- 1
Contraindicated (1)
- Abiraterone Acetate + Thioridazine— CYP2D6 substrate with narrow therapeutic index. Avoid co-administration with abiraterone acetate.
Major (2)
- Abiraterone Acetate + Dextromethorphan— CYP2D6 substrate with 2.8-fold increase in Cmax and 2.9-fold increase in AUC when co-administered. Avoid co-administrati…
- Abiraterone Acetate + Rifampin— Strong CYP3A4 inducer decreased abiraterone exposure by 55%. Avoid concomitant use or increase abiraterone dosing freque…
Moderate (1)
- Abiraterone Acetate + Pioglitazone— CYP2C8 substrate with 46% AUC increase when co-administered. Monitor closely for toxicity, especially if narrow therapeu…
Minor (1)
- Abiraterone Acetate + Ketoconazole— Strong CYP3A4 inhibitor had no clinically meaningful effect on abiraterone pharmacokinetics.